(Camptothecin + podofilox) is under clinical development by Neovia Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Camptothecin + podofilox)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Camptothecin + podofilox) overview

Fixed dose combination of camptothecin and podofilox (NEV-801) is under development for the treatment of advanced malignancy and solid tumors. It is administered through intravenous route. Podophyllotoxin acts by targeting DNA topoisomerase II whereas camptothecin acts by targeting DNA topoisomerase I. It was also under development for the treatment of ovarian cancer, resistant colorectal cancer, non-small cell lung cancer and targeted-therapy resistant chronic myeloid leukemia.

For a complete picture of (Camptothecin + podofilox)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.